Navigation Links
Cryo-Cell International, Inc. Reports First Quarter 2009 Results
Date:4/9/2009

Company Reports Quarterly Net Income of $536,000

OLDSMAR, Fla., April 9 /PRNewswire-FirstCall/ -- Cryo-Cell International, Inc. (OTC Bulletin Board: CCEL) (the "Company"), one of the world's largest and most established family cord blood banks, today announced results for the first quarter ended February 28, 2009. Consolidated revenues for the first quarter of fiscal 2009 were approximately $3.9 million compared to approximately $4.2 million for the first quarter of fiscal 2008. The Company reported net income in the first quarter of fiscal 2009 of approximately $536,000, or $0.05 per basic common share, compared to a net loss of approximately ($247,000), or ($0.02) per basic common share, in the first fiscal quarter of fiscal 2008. The net income in the first quarter of fiscal 2009 is primarily the result of a 23% decrease in marketing, general and administrative expenses and a 23% decrease in cost of sales.

The Company recognized approximately $338,000 in licensee income for the first quarter of fiscal 2009, compared to approximately $183,000 for the same period in 2008. Of the licensee income for the first quarter of fiscal 2009, $100,000 was related to an installment of a non-refundable up-front license fee from the licensee of the Company's U-Cord program in Venezuela. The remaining approximately $238,000 is royalty income earned on subsequent processing and storage of specimens in geographical areas where the Company has license agreements, and from the sale of sub-license agreements by licensees. Licensee income for the same period in 2008 consisted of approximately $183,000 of royalty income earned on the subsequent processing and storage of specimens in geographical areas where the Company has license agreements, and from the sale of sub-license agreements by licensees.

As of February 28, 2009, the Company had approximately $5.7 million in available cash, c
'/>"/>

SOURCE Cryo-Cell International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Cryo-Cell Renews Upromise Industry-Exclusive Agreement
2. Cryo-Cell International, Inc. Reports Third Quarter 2008 Results
3. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
4. Cryo-Cell International, Inc. Reports Second Quarter 2008 Results
5. Cryo-Cell International, Inc. Reports First Quarter 2008 Results
6. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
7. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
8. MINRAD International, Inc. Announces Reduction in Workforce
9. Medizone International, Inc. Announces Establishment of Canadian Foundation for Global Health
10. Sangui Biotech International, Inc., Reports Sales Decrease, Continued Losses
11. China Yingxia International, Inc. Announces $2 Million Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2013)... Dennis R. HIll M.D. Radiation Oncologist at the Alta ... there has been a promotion of the idea that a ... or low dose rate, brachytherapy for prostate cancer. The claim ... shorter half life, and gives a higher biologically effective dose ... a higher average energy than the other commonly used prostate ...
(Date:5/24/2013)... , May 24, 2013 InspireMD, ... in embolic protection stents, announced that Alan Milinazzo ... Craig Shore , the Company,s Chief Financial ... Conference on Thursday May 30, 2013 at The Pfister Hotel, ... The format of the conference includes a number ...
(Date:5/24/2013)... 24, 2013 The Oklahoma tornado ... its ravage, the mayor of Moore, one of the heavily ... said a report from cnn.com. Reaching out to also be ... Molderizer and Safe Shield to counter the looming mold problem. ... on May 22, 2013, caused 24 deaths, My Cleaning Products ...
(Date:5/23/2013)... their baby stopped breathing, his collapsed bronchus blocking the ... Bryan Gionfriddo watched helplessly, just praying that somehow the ... said he had a good chance of not leaving ... 20-month-old son, Kaiba. "At that point, we were desperate. ... run with it." , They found hope at the ...
Breaking Biology Technology:Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same 2Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same 3InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3
... - Sales up 16% - Profit Before R&D up 19% - Net Profit (Group Share) up 12% - ... approved the 2007 consolidated financial statements:, (EUR millions) 2007 ... ... sales % change, Sales ...
... 12 Oncolys BioPharma,Inc. (Tokyo, Japan) and Tacere ... they have entered into a strategic alliance and,license ... interference (RNAi)-based Hepatitis C virus (HCV) compound, TT-033,code-named ... the,strategic alliance entered into by Tacere and Oncolys ...
... 12 Mercury Therapeutics,Inc. (MTI), a company that ... announces that it has signed an exclusive license,agreement ... Under this agreement, MTI has licensed to ... AMP-activated protein kinase (AMPK), a well,validated drug target ...
Cached Biology Technology:STALLERGENES : Further Profit Growth Acceleration of R&D Expenditure 2STALLERGENES : Further Profit Growth Acceleration of R&D Expenditure 3Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug 2Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug 3Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences 2Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences 3
(Date:5/22/2013)... Legionella pneumophila bacteria is responsible for legionellosis, an ... to infect us, this pathogen has developed a complex ... in our cells, thus avoiding these acting against the ... research centre, CIC bioGUNE, in which teams from the ... the National Supercomputation Centre in Barcelona (BSC) have also ...
(Date:5/22/2013)... Irvine, Calif., May 22, 2013 Early screening for ... personal pregnancy testing is for women, thanks to UC ... the American Chemical Society . , After more than ... a way to clearly identify clinically usable markers for ... be detected far sooner, with greater accuracy and at ...
(Date:5/22/2013)... YORK, May 22, 2013. Plastic additives known as ... about everywhere: They turn up in flooring, plastic ... to the Centers for Disease Control and Preventionthe ... phthalates have come under increasing scrutiny. A growing ... (which can leech from packaging and mix with ...
Breaking Biology News(10 mins):Mechanism discovered which aids Legionella to camouflage itself in the organism 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2
... European biomedical research infrastructures (BMS ESFRIs) by investing in ... linking to the EU level initiatives in developing biobanking ... This investment follows the 3-year pan-European planning phase, ... completed in 2010. The approach that Finland ...
... ITHACA, NY Commercial apple growers in the northeastern ... and insect invasions to tree nutrition and crop load. ... of integrated fruit production (IFP) and organic fruit production ... alternative markets. In a recent issue of HortScience ...
... world to lessen the environmental impact of urbanization, green ... aesthetic benefits. A new study from researchers at Colorado ... in HortScience evaluated six plant species to ... roofs in Colorado. Five plants that survived the 2-year ...
Cached Biology News:Finland initiates European biomedical research infrastructures construction with $6.7 million for 2011 2Finland initiates European biomedical research infrastructures construction with $6.7 million for 2011 3Integrated, organic production systems evaluated for 'liberty' apple 25 standout species for extensive green roofs 2
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
... to just 15 minutes! The name Instant ... be drawn between this exciting new laboratory concept ... Instant meals consumed by astronauts, explorers and ... reconstituted by adding water. The Instant ELISA ...
Request Info...
Request Info...
Biology Products: